|
Feb 20
|
Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock
|
|
Feb 20
|
Halozyme Therapeutics Full Year 2024 Earnings: Beats Expectations
|
|
Feb 19
|
HALO's Q4 Earnings Beat, Higher Royalties Drive Revenue Growth
|
|
Feb 19
|
Q4 2024 Halozyme Therapeutics Inc Earnings Call
|
|
Feb 19
|
Halozyme Therapeutics Inc (HALO) Q4 2024 Earnings Call Highlights: Record Revenue and Strong ...
|
|
Feb 18
|
Halozyme Therapeutics (HALO) Reports Q4 Earnings: What Key Metrics Have to Say
|
|
Feb 18
|
Halozyme Therapeutics (HALO) Q4 Earnings and Revenues Top Estimates
|
|
Feb 18
|
Halozyme Therapeutics: Q4 Earnings Snapshot
|
|
Feb 18
|
Recursion Pharmaceuticals Stock Scores RS Ratings Over 90
|
|
Feb 18
|
Incyte Stock Sees Relative Strength Rating Rise To 71
|
|
Feb 18
|
HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS
|
|
Feb 17
|
Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast?
|
|
Feb 13
|
HALO Gears Up to Report Q4 Earnings: Here's What You Should Know
|
|
Feb 12
|
Here's How Much You'd Have If You Invested $1000 in Halozyme Therapeutics a Decade Ago
|
|
Feb 12
|
Halozyme Therapeutics, Inc. (HALO): A Cheap Biotech Stock to Invest In Now
|
|
Jan 1
|
Exploring 3 Prominent High Growth Tech Stocks In The United States
|
|
Dec 30
|
Halozyme Announces Takeda Received Regulatory Approval for HYQVIA® 10% Subcutaneous Injection Set with ENHANZE® in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
|
|
Dec 30
|
Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy
|
|
Dec 30
|
Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (nivolumab) Indications
|
|
Oct 14
|
Implied Volatility Surging for Halozyme Therapeutics (HALO) Stock Options
|